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Protocadherin-7 contributes to maintenance of bone 
homeostasis through regulation of osteoclast multinucleation
Hyunsoo Kim1,#, Noriko Takegahara1,#, Matthew C. Walsh1, Jun Ueda2, Yoshitaka Fujihara2, Masahito Ikawa2 & 
Yongwon Choi1,*
1Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, 
USA, 2Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan
Osteoclasts are hematopoietic-derived cells that resorb bone. 
They are required to maintain proper bone homeostasis and 
skeletal strength. Although osteoclast differentiation depends 
on receptor activator of NF-B ligand (RANKL) stimulation, 
additional molecules further contribute to osteoclast maturation. 
Here, we demonstrate that protocadherin-7 (Pcdh7) regulates 
formation of multinucleated osteoclasts and contributes to main-
tenance of bone homeostasis. We found that Pcdh7 expression 
is induced by RANKL stimulation, and that RNAi-mediated 
knockdown of Pcdh7 resulted in impaired formation of osteo-
clasts. We generated Pcdh7-deficient mice and found increased 
bone mass due to decreased bone resorption but without any 
defect in bone formation. Using an in vitro culture system, it 
was revealed that formation of multinucleated osteoclasts is 
impaired in Pcdh7-deficient cultures, while no apparent defects 
were observed in differentiation and function of Pcdh7-deficient 
osteoblasts. Taken together, these results reveal an osteoclast 
cell-intrinsic role for Pcdh7 in maintaining bone homeostasis. 
[BMB Reports 2020; 53(9): 472-477]
INTRODUCTION
Skeletal homeostasis is maintained via continuous bone for-
mation mediated by osteoblasts and bone destruction mediated 
by osteoclasts (1). Under pathogenic conditions, excessive 
osteoclast activity is often observed, which can cause patho-
genic bone loss such as is observed in osteoporosis, perio-
dontitis, and rheumatoid arthritis (2-4). Therefore, understanding 
the cellular and molecular mechanisms that regulate osteoclast 
differentiation and function will contribute to our knowledge 
of osteoclast biology, and further provide molecular bases for 
designing therapeutic strategies for bone diseases that are 
accompanied by bone destruction. 
Osteoclasts are specialized multinucleated giant cells that 
originate from myeloid progenitors (5). Differentiation of 
osteoclasts is initiated primarily by the osteoclast differentiation 
factor RANKL (6), but the process further requires cell surface 
molecules to mediate cell adhesion and promote osteoclast 
multinucleation (7), which is itself a hallmark of osteoclast 
maturation (8). One of the principal factors at sites of cell-cell 
contact are cadherins. Cadherins are transmembrane, calcium- 
dependent adhesion molecules that regulate cell-cell contact 
through homophilic or heterophilic interactions between compa-
tible cadherin extracellular regions (9, 10). The cadherin super-
family consists of classical cadherins, desmosomal cadherins, 
and protocadherins. 
Previously, we reported comparative gene expression profiling 
designed to identify potential genes that regulate osteoclast 
maturation through use of multinucleation as a functional readout 
(8). As a result, the gene Pcdh7, which encodes the protein 
protocadherin 7 (Pcdh7) was identified (Supplementary Fig. 1). 
Pcdh7 is a member of non-clustered protocadherin 1 subgroup 
of the cadherin superfamily (11, 12). It has seven cadherin-like 
ectodomains, a single transmembrane domain and a C-terminal 
intracellular domain (13). The expression of Pcdh7 has been 
identified in osteoclasts, and a potential regulatory role in 
osteoclast multinucleation has been revealed by RNAi-medi-
ated gene knockdown (14). However, the function of Pcdh7 in 
regulation of osteoclast differentiation in vivo and its role in 
bone homeostasis still remain unclear.
Here, we demonstrate that Pcdh7, expression of which is 
induced by RANKL stimulation, functions as a regulator of 
bone homeostasis through regulation of osteoclast multinucle-
ation. Gene deletion of Pcdh7 resulted in increased bone mass 
with reduction of osteoclasts but not of osteoblasts in mice. No 
apparent defects in bone formation were observed. Using in 
vitro cell culture systems, we showed that Pcdh7 deficiency 
results in impaired formation of multinucleated osteoclasts, 
and that the defect could be restored by retroviral transduction 
of Pcdh7. By contrast, Pcdh7 deficiency did not show signifi-
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Fig. 1. Identification of Pcdh7 as an osteoclast differentiation associ-
ated gene. (A) PCDH7 protein expression during osteoclast differen-
tiation. Total cell lysates were prepared from BMMs cultured with 
M-CSF + RANKL for the indicated days and used for western 
blotting with the indicated antibodies. (B) Effect of Pcdh7 RNAi on 
osteoclast differentiation. BMMs retrovirally transduced with the 
indicated shRNAs were cultured with M-CSF + RANKL for three 
days. Relative expression of Pcdh7 was determined by Q-PCR (left). 
Cells were stained for TRAP (middle). Frequency of TRAP+ multinu-
cleated cells is shown (right). Scale bar represents 100 m. 
Fig. 2. Pcdh7 deficiency results in increased bone mass in mice. (A) Microcomputed tomography (CT) images of femurs from Pcdh7+/+ and Pcdh7−/−
mice. The femurs of 12-week-old male mice were analyzed. Bone volume per tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular 
number (Tb.N), and trabecular spacing (Tb.Sp) are shown. (B) Microcomputed tomography (CT) images of femurs cortical thickness (Ct.Th) 
from 12-week-old male Pcdh7+/+ and Pcdh7−/− mice is shown. (C) Dynamic histomorphometry of tibias from 12-week-old Pcdh7+/+ and 
Pcdh7−/− mice. Mineral apposition rate (MAR) and bone formation (BFR) are shown. Scale bar represents 50 m. (D) Histological analysis of tibias 
from 12-week-old Pcdh7+/+ and Pcdh7−/− mice. Tibial sections were stained with TRAP or H&E. Osteoclast number per bone surface (N.Oc/ 
BS) and osteoblast number per bone surface (N.Ob/BS) are shown. Data are shown as mean ± S.D. *P ＜ 0.05, **P ＜ 0.01, ***P ＜ 0.001.
cant differences in differentiation or function of osteoblasts. 
Collectively, these results demonstrate that Pcdh7 controls 
osteoclast multinucleation/maturation and contributes to main-
tenance of bone homeostasis.
RESULTS
Pcdh7 is involved in in vitro osteoclast differentiation
In order to understand the role of Pcdh7 in osteoclasts, 
expression dynamics of Pcdh7 during osteoclast differentiation 
were examined. Mouse bone marrow-derived monocytes 
(BMMs) were treated with M-CSF + RANKL for up to three 
days to induce osteoclasts, and then western blotting was 
performed. Expression of PCDH7 protein was induced, and 
peaked on day one of culture (Fig. 1A).  Next, we investigated 
the role of Pcdh7 in osteoclasts by RNAi experiments using 
retrovirus encoding shRNA for Pcdh7. BMMs retrovirally 
transduced with shRNA for Pcdh7 showed significant reduc-
tions in tartrate-resistant acidic phosphatase positive (TRAP+) 
multinucleated cells (i.e., mature osteoclasts) (Fig. 1B), consis-
tent with a previous report (14). These results suggested a 
potential regulatory function of Pcdh7 in osteoclast maturation. 
Pcdh7 regulates bone homeostasis 
To better understand the role of Pcdh7 in osteoclasts and its 
function in bone remodeling, Pcdh7-deficient (Pcdh7−/−) mice 
were generated using clustered regularly interspersed short 
palindromic repeats (CRISPR)/Cas9 technology (Supplementary 
Fig. 2A). Gene knockout mice carrying deletions of 14 base 
pairs (bps) in exon 1 of Pcdh7 were obtained (Supplementary 
Fig. 2B). We verified mouse genotypes by genome sequencing, 
and also confirmed successful gene deletion of Pcdh7 in 
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Fig. 3. Pcdh7 deficiency results in impaired osteoclast differentiation but not osteoblast differentiation or function. (A) Relative expression of 
Pcdh7 in BMMs, osteoclasts (three days culture with M-CSF + RANKL), BMSCs, and osteoblasts (14 days culture with glycerophosphate + 
ascorbic acid). Total RNAs were collected and expression of Pcdh7 was measured by Q-PCR. (B) Osteoclast differentiation of Pcdh7+/+
and Pcdh7−/− cells. BMMs were cultured with M-CSF + RANKL for three days. Frequency of TRAP+ multinucleated cells (3 nuclei or more 
per cell) and hyper-multinucleated cells (＞100 m) are shown. (C) Gene expression during osteoclast differentiation. Total RNAs were 
collected from Pcdh7+/+ and Pcdh7−/− cultures and indicated genes were measured by Q-PCR. (D) Bone resorption activity of Pcdh7+/+
and Pcdh7−/− osteoclasts. Resorption area per cell is shown. (E) Osteoclast differentiation rescued by retroviral transduction of Pcdh7 in 
Pcdh7−/− BMMs. BMMs were retrovirally transduced with empty vector (EV) or Flag-tagged Pcdh7 expression vector followed by culture 
with M-CSF + RANKL for three days. Frequency of TRAP+ multinucleated cells (3 nuclei or more per cell) is shown. Expression of exo-
geneous Pcdh7 was confirmed by western blotting with anti-Flag antibody. (F) Pcdh7+/+ and Pcdh7−/− BMSCs were cultured with osteo-
genic medium for the indicated days, and then stained with alizarin red. (G) Gene expression during osteoblast differentiation. Total RNAs 
were collected from Pcdh7+/+ and Pcdh7−/− cultures and indicated genes were measured by Q-PCR. (H) Pcdh7+/+ and Pcdh7−/− BMMs 
and BMSC-derived osteoblasts were cocultured in the presence of 1,25-dihydroxyvitamin D3 and prostaglandin E2, and the formation of 
multinucleated osteoclasts was determined by TRAP staining. Frequency of TRAP+ multinucleated cells (3 nuclei or more per cell) are shown. 
Data are shown as mean ± S.D. *P ＜ 0.05, ***P ＜ 0.001. 
Pcdh7−/− cultures by western blotting (Supplementary Fig. 2C).
In order to examine the impact of Pcdh7 deficiency on bone 
homeostasis, gender- and age-matched Pcdh7+/+ and Pcdh7−/− 
mice were prepared and representative 3D trabecular bone 
reconstruction analyses were performed. Bone microstructure 
imaging by high-resolution microcomputed tomography (CT) 
of Pcdh7−/− mice revealed increases in bone mass, characterized 
by augmented bone indices including trabecular bone volume 
per tissue volume (BV/TV) and trabecular thickness (Tb.Th), 
with concomitant decreases in trabecular spacing (Tb.Sp) (Fig. 
2A). Trabecular number (Tb.N) was comparable between 
Pcdh7+/+ and Pcdh7−/− mice (Fig. 2A). There were no signifi-
cant differences in cortical bone thickness (Ct.Th) between 
Pcdh7+/+ and Pcdh7−/− mice (Fig. 2B). Dynamic histomorpho-
metry by sequential injection of calcein and xylenol orange 
revealed that bone formation rates is normal in Pcdh7−/− mice 
(Fig. 2C). Osteoclasts and osteoblasts in Pcdh7+/+ and Pcdh7−/− 
mice were enumerated using bone sections. TRAP-stained 
bone sections exhibited a reduction in osteoclast numbers on 
the bone surface (N.Oc/BS) in Pcdh7−/− bone compared to 
numbers in Pcdh7+/+ (Fig. 2D). By contrast, quantitation of 
osteoblast numbers per bone surface (N.Ob/BS) revealed 
comparable numbers of osteoblasts in bone sections between 
Pcdh7+/+ and Pcdh7−/− mice (Fig. 2D). These results suggest 
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Fig. 4. A summarizing diagram. Deficiency of Pcdh7 results in in-
creased bone mass with reduction of osteoclasts but not of osteo-
blasts in mice.
that Pcdh7 deficiency results in increased bone mass with 
impaired osteoclast differentiation but apparently normal 
osteoblast development and function in male mice.
Cell-intrinsic role of Pcdh7 in osteoclast differentiation
To further characterize the specific cell-intrinsic role of Pcdh7, 
osteoclasts and osteoblasts were generated in vitro, and differ-
entiation and cellular functions were examined. First, expression 
levels of Pcdh7 message in osteoclasts and osteoblasts were 
examined. Pcdh7+/+ BMMs or bone marrow-derived stromal 
cells (BMSCs) were cultured, respectively, with M-CSF + 
RANKL to generate osteoclasts, or with glycerophosphate + 
ascorbic acid to generate osteoblasts. Pcdh7 message was 
significantly increased in osteoclasts cultures compared to 
levels in BMMs, while Pcdh7 message levels were lower in 
BMSCs or BMSC-derived osteoblasts than in BMMs (Fig. 3A). 
Next, osteoclasts were generated from Pcdh7+/+ and Pcdh7−/− 
BMMs with M-CSF + RANKL. Significant reductions in the 
frequency of multinucleated (＞3 nuclei per cell) TRAP+ cells 
in Pcdh7−/− cultures were observed compared to Pcdh7+/+ 
cultures (Fig. 3B). Message levels of osteoclast differentiation 
markers, Acp5 and Ctsk, were comparable between Pcdh7+/+ 
and Pcdh7−/− cultures (Fig. 3C). Formation of pit area per 
mature osteoclasts was slightly reduced in Pcdh7−/− cultures 
(Fig. 3D). These results suggest that Pcdh7 is required for 
osteoclast multinucleation rather than for differentiation or 
bone resorbing functions. Retroviral transduction of Pcdh7−/− 
BMMs with full-length Pcdh7 completely rescued TRAP+ 
multinucleated cell formation in Pcdh7−/− cultures (Fig. 3E), 
suggesting that the phenotypes observed in Pcdh7−/− osteoclast 
cultures can be solely attributed to deletion of the Pcdh7 gene.
Next, osteoblasts were generated from Pcdh7+/+ and Pcdh7−/− 
BMSCs with glycerophosphate + ascorbic acid. In vitro osteo-
genic differentiation assays with alizarin red staining revealed 
no differences in terms of mineralized nodule formation and 
calcium deposits in Pcdh7+/+ and Pcdh7−/− osteoblasts (Fig. 
3F). Message levels of osteoblast differentiation markers such 
as Alpl, osteocalcin (also known as Bglap), and Bmp2 were 
also comparable between Pcdh7+/+ and Pcdh7−/− cells (Fig. 
3G). Additionally, when BMSC-derived osteoblasts were co-
cultured with BMMs in the presence of 1,25-dihydroxyvitamin 
D3 + prostaglandin E2, Pcdh7−/− osteoblasts promoted the 
formation of Pcdh7+/+ osteoclasts to the same extent as 
Pcdh7+/+ osteoblasts (Fig. 3H). These results suggest that 
Pcdh7 is not required for osteoblast differentiation or function. 
Taken together, these results clarify the role of Pcdh7 in bone 
homeostasis as a regulator of osteoclast multinucleation/matu-
ration, but not of osteoblast differentiation or function.
DISCUSSION
Cell-cell interaction through surface receptors is required for 
proper osteoclast differentiation and multinucleation (7, 15-17). 
In this study, we demonstrated that Pcdh7, a transmembrane 
protein belonging to the protocadherins within the cadherin 
superfamily, is required for proper bone homeostasis through 
regulation of osteoclast multinucleation/maturation (Fig. 4). 
We generated Pcdh7 gene deletion mice and revealed that 
Pcdh7 deficiency resulted in increased bone mass without 
affecting bone formation in male mice. Determining whether 
the requirement for Pcdh7 for proper bone homeostasis is 
influenced by sexual difference will need further investigation. 
Employing an in vitro culture system using Pcdh7-deficient 
cells further revealed a requirement for Pcdh7 in osteoclast 
multinucleation, while Pcdh7 deficiency resulted in no signifi-
cant impact on osteoblast differentiation or function. A previous 
report identified Pcdh7 as a gene that is epigenetically regulated 
during osteoclastogenesis, and implied a role for Pcdh7 in 
osteoclast multinucleation (14). Our findings reported here are 
consistent with those previously reported findings with respect 
to the role of Pcdh7 in osteoclast multinucleation, and provide 
the first in vivo evidence of involvement of Pcdh7 in bone 
homeostasis.
We have identified an osteoclast cell-intrinsic role of Pcdh7. 
However, the principal function and molecular mechanism of 
Pcdh7 in the context of osteoclast differentiation/multinucleation 
still remain to be determined. Cadherins function by mediating 
cell-cell adhesion through homophilic interactions, whereas 
protocadherins appear to have more varied physiological 
functions as mediators of both cell-cell adhesion and as 
regulators of signaling molecules (12, 18, 19). Indeed, in 
addition to exhibiting binding capacity via homophilic inter-
actions (20), Pcdh7 has been shown to control signal trans-
duction pathways via binding cytoplasmic signaling molecules 
such as SET (also known as TAF1) and PP2a (21). Involvement 
of PP2a in osteoclasts has been shown using a chemical 
inhibitor (22), and the findings suggest that Pcdh7 regulates 
PP2a during osteoclast differentiation. There is another possibility 
that the Pcdh7 intracellular region recruits additional signaling 
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molecules. Pcdh7 has been shown to express four unique 
isoforms with different cytoplasmic tails that are generated by 
alternative splicing (23). It is unclear which isoform(s) is 
expressed in osteoclasts, and whether the different isoforms 
have functional differences. Further studies will be required to 
understand the molecular mechanisms of Pcdh7-mediated 
regulation of osteoclast maturation. 
 Bone remodeling is tightly controlled by coupling between 
bone resorbing osteoclasts and bone forming osteoblasts (24, 
25). Coupling is critical for preserving bone architecture and 
strength. Current treatments for bone loss such as bisphospho-
nate and anti-RANKL antibody (Denosmab), which primarily 
target early osteoclast commitment and/or viability (26), often 
fail to uncouple bone degradation and formation. Consequently, 
bone strength is compromised due to unintended inhibition of 
coupled bone formation (27). In this study, we report having 
identified Pcdh7 in the process of searching for genes related 
to the maturation/late stage of osteoclast development, which 
we believe will lead to better treatment targets (i.e., inhibition 
of osteoclastic bone resorption without preventing osteoblastic 
new bone formation), and we have shown that Pcdh7 uncouples 
bone degradation and formation. Our results suggest that Pcdh7 
might be a good candidate target for selectively inhibiting 
bone loss. 
Taken together, although a full understanding of how Pcdh7 
contributes to osteoclast differentiation remains to be addressed, 
we provide evidence of a non-redundant function for Pcdh7 in 
osteoclast multinucleation/maturation and bone homeostasis. 
Pcdh7 may be a promising candidate for a therapeutic target 
for bone diseases.
MATERIALS AND METHODS
Detailed information is provided in the Supplementary Informa-
tion.
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